The Feasibility Of Expectant Management Versus Induction At 38 Weeks Among Individuals With Gestational Diabetes Mellitus: A Randomized Controlled Pilot Trial (EAGER Pilot Trial)

NCT ID: NCT06641141

Last Updated: 2025-11-18

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 260 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-04-07
• Study Completion Date: 2028-03-31

Brief Summary

The EAGER pilot trial is designed to assess the feasibility of a Canadian, multicentre prospective randomized open-label blinded end-point (PROBE) clinical trial addressing whether induction of labour (IOL) at 38 weeks' gestation compared to expectant management (EM) reduces severe perinatal mortality and morbidity among individuals with gestational diabetes mellitus (GDM). Eligible participants will be consented between 32 weeks + 0 days and 38 weeks + 0 days gestation and randomized between 36 weeks + 0 days and 38 weeks + 0 days gestation. Participants will be randomized to one of two arms:

• Intervention Arm: IOL between 38 weeks + 0 days and 38 weeks + 6 days OR
• Control Arm: EM without intervention until spontaneous labour, or earlier if a medical indication arises.

A total of 260 participants (130 per group) will be recruited from Canadian sites, where participants will have 3 study visits:

1. Enrollment and randomization

2. After delivery and up to 72 hours postpartum

3. 6 weeks postpartum At enrollment and randomization, patient-reported baseline and clinical data from medical charts will be collected. Upon admission to hospital for labour and delivery, a blood sample may be collected to assess HbA1C and plasma glucose levels. After delivery and up to 72 hours postpartum, study feasibility will be assessed through patient-reported outcomes and administrative and clinical data. At 6 weeks postpartum, participants will be surveyed for secondary health resource use. Findings from this pilot will inform the design, implementation and feasibility of a future full-scale randomized controlled trial.

Conditions

Gestational Diabetes Mellitus (GDM)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: SINGLE

Study Groups

Induction of Labour between 38 weeks + 0 days and 38 weeks + 6 days

Induction of Labour between 38+0 weeks and 38+6 weeks.

Group Type: EXPERIMENTAL

Induction of Labour

Intervention Type: PROCEDURE

Induction of Labour (IOL) will occur between 38+0 weeks and 38+6 weeks. All participating sites will follow an evidence-based approach for IOL, which may include any of the following: use of prostaglandins, oxytocin, amniotomy, or intracervical balloon catheters with and without extra-amniotic saline infusion for the intervention arm. Participants who are induced in either the intervention or control arms will be managed by their delivery care provider to ensure sufficient time to labour and determine when to proceed to Cesarean delivery. What constitutes a "failed" IOL will be dictated by local clinical practice guidelines and will be informed by the time since IOL (24-48 hours) and/or physician diagnosis of labour dystocia.

Expectant Management

Expectant management without intervention until spontaneous labour, or earlier at the discretion of the attending healthcare provider.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Induction of Labour

Induction of Labour (IOL) will occur between 38+0 weeks and 38+6 weeks. All participating sites will follow an evidence-based approach for IOL, which may include any of the following: use of prostaglandins, oxytocin, amniotomy, or intracervical balloon catheters with and without extra-amniotic saline infusion for the intervention arm. Participants who are induced in either the intervention or control arms will be managed by their delivery care provider to ensure sufficient time to labour and determine when to proceed to Cesarean delivery. What constitutes a "failed" IOL will be dictated by local clinical practice guidelines and will be informed by the time since IOL (24-48 hours) and/or physician diagnosis of labour dystocia.

Intervention Type: PROCEDURE

Other Intervention Names

IOL; Induction

Eligibility Criteria

Inclusion Criteria

• Diagnosis of GDM after 24 weeks of gestation, based on documented 1-step or 2-step screening and diagnostic tests for GDM.
• Singleton fetus at randomization.
• Confirmed live fetus within 24 hours prior to randomization.
• Gestational age between 36 weeks + 0 days and 38 weeks + 0 days inclusive based on an ultrasound in the first or second trimester [≤ 23 weeks + 0 days]. For pregnancies conceived by in vitro fertilization, dating will be based on the embryo age at transfer.
• Cephalic presentation.
• Planning to deliver at a participating site.
• Aged 16 years or older.

Exclusion Criteria

• Pre-pregnancy diabetes mellitus.
• Any obstetrical/maternal indication for immediate delivery including placenta abruption, abnormal fetal well-being either by non-stress test or biophysical profile, history of venous thromboembolism (VTE) on low molecular weight heparin, pre-existing hypertension, gestational hypertension, preeclampsia, eclampsia, or Hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome at the time of randomization.
• Contraindication to labour and/or vaginal delivery.
• Signs of labour (regular uterine contractions accompanied by cervical dilation and/or effacement) at the time of randomization.
• Significant vaginal bleeding or ruptured membranes at the time of randomization.
• Prior Cesarean delivery.
• Placenta previa, placenta accreta, or vasa previa.
• Cerclage in current pregnancy.
• Known major fetal anomaly (e.g., gastroschisis, congenital heart defects).
• Known oligohydramnios (AFI < 5 or MVP < 2 or no 2 by 2 pocket).
• Known fetal growth restriction (EFW < 3rd percentile).
• Refusal of blood products.
• Use of unregulated substances.

• Minimum Eligible Age: 16 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Ottawa Hospital Research Institute

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mark C Walker, MD, MSc, MHM

Role: PRINCIPAL_INVESTIGATOR

Ottawa Hospital Research Institute

Darine El-Chaâr, MD, FRCS(C), MSc

Role: PRINCIPAL_INVESTIGATOR

Ottawa Hospital Research Institute

Locations

The Ottawa Hospital

Ottawa, Ontario, Canada

Site Status: RECRUITING

Countries

Canada

Central Contacts

Malia Murphy, PhD

Role: CONTACT

malmurphy@ohri.ca

613-737-8899

Serine Ramlawi, MSc

Role: CONTACT

sramlawi@ohri.ca

613-737-8899 ext. 73840

Facility Contacts

Ruth Rennicks White

Role: primary

rwhite@toh.ca

613-737-8899 ext. 78663

Other Identifiers

PJT-191790

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

CTO 4937

Identifier Type: -

Identifier Source: org_study_id